Sarepta Therapeutics’ CEO Doug Ingram said Wednesday he would retire after a tumultuous decade in which he turned the biotech into a $15 billion company by pushing three different treatments for Duchenne muscular dystrophy to approval and then watched that value collapse amid investigations into the safety of its gene therapy and the emergence of superior versions of its other products.
The company is currently searching for a successor. Ingram will retire by the end of the year, if a new CEO is not found before then.
On an earnings call, Ingram said he was leaving because his wife and son were recently diagnosed with myotonic dystrophy, a form of muscular dystrophy that Sarepta started working on in 2024 through a new partnership.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
